Morpheus8
InMode
face, neck, body, acne scars
Morpheus8 vs. Potenza
Last verified 7/30/2026
Potenza
Cynosure / Jeisys Medical
face, neck, body, scars
Quick comparison
| Attribute | Morpheus8 | Potenza |
|---|---|---|
| Mechanism | Fractional radiofrequency microneedling | Fractional radiofrequency microneedling |
| Typical sessions | Often delivered as a series, but a universal session count is not established by the FDA clearance; protocol depends on indication and settings. | Often used in a series, but no universal session count is established by the US clearance. |
| Downtime | Redness, swelling, crusting, pinpoint bleeding, tenderness, and temporary track marks can occur; deeper or higher-energy treatment can extend recovery. | Redness, swelling, tenderness, pinpoint bleeding, crusting, and temporary needle marks can occur. |
Mechanism
- Morpheus8
- Fractional radiofrequency microneedling
- Potenza
- Fractional radiofrequency microneedling
Typical sessions
- Morpheus8
- Often delivered as a series, but a universal session count is not established by the FDA clearance; protocol depends on indication and settings.
- Potenza
- Often used in a series, but no universal session count is established by the US clearance.
Downtime
- Morpheus8
- Redness, swelling, crusting, pinpoint bleeding, tenderness, and temporary track marks can occur; deeper or higher-energy treatment can extend recovery.
- Potenza
- Redness, swelling, tenderness, pinpoint bleeding, crusting, and temporary needle marks can occur.
Benefits and trade-offs
Morpheus8
- May remodel texture, scars, and laxity through combined needle injury and thermal coagulation; exact use depends on tip and settings.
- It does not add filler volume and its 510(k) clearance does not establish superiority over other RF-microneedling devices.
- Device branding can obscure how strongly depth, energy, passes, tip, and provider judgment determine both result and risk.
Potenza
- Can create fractional needle and thermal injury used in clinician-directed resurfacing or remodelling protocols.
- It does not add volume, and the US clearance does not itself establish a wrinkle, acne-scar, or tightening indication.
- Many public claims describe cosmetic outcomes that are not the same as the device's narrow US cleared indication.
Details
Open a section for more context. Sources appear beside the claims they support.
How the skin is treated
| Attribute | Morpheus8 | Potenza |
|---|---|---|
| How it works | Programmable needle electrodes penetrate tissue and deliver fractional bipolar radiofrequency, creating discrete zones of thermal coagulation at selected depths.
| Microneedle electrodes enter tissue and deliver monopolar or bipolar radiofrequency through selected insulated or non-insulated tip configurations, producing controlled coagulation.
|
| What it primarily changes | May remodel texture, scars, and laxity through combined needle injury and thermal coagulation; exact use depends on tip and settings.
| Can create fractional needle and thermal injury used in clinician-directed resurfacing or remodelling protocols.
|
| What it does not change | It does not add filler volume and its 510(k) clearance does not establish superiority over other RF-microneedling devices.
| It does not add volume, and the US clearance does not itself establish a wrinkle, acne-scar, or tightening indication.
|
| Expected result magnitude | Variable; depends more on protocol and indication than on device name alone.
| Variable and protocol dependent.
|
How it works
- Morpheus8
- Programmable needle electrodes penetrate tissue and deliver fractional bipolar radiofrequency, creating discrete zones of thermal coagulation at selected depths.
- FDA 510(k) Summary K231790: Morpheus8 · accessdata.fda.gov
- Potenza
- Microneedle electrodes enter tissue and deliver monopolar or bipolar radiofrequency through selected insulated or non-insulated tip configurations, producing controlled coagulation.
- FDA 510(k) Summary K192545: Potenza · accessdata.fda.gov
What it primarily changes
- Morpheus8
- May remodel texture, scars, and laxity through combined needle injury and thermal coagulation; exact use depends on tip and settings.
- FDA 510(k) Summary K231790: Morpheus8 · accessdata.fda.gov
- Potenza
- Can create fractional needle and thermal injury used in clinician-directed resurfacing or remodelling protocols.
- FDA 510(k) Summary K192545: Potenza · accessdata.fda.gov
What it does not change
- Morpheus8
- It does not add filler volume and its 510(k) clearance does not establish superiority over other RF-microneedling devices.
- FDA 510(k) Summary K231790: Morpheus8 · accessdata.fda.gov
- Potenza
- It does not add volume, and the US clearance does not itself establish a wrinkle, acne-scar, or tightening indication.
- FDA 510(k) Summary K192545: Potenza · accessdata.fda.gov
Expected result magnitude
- Morpheus8
- Variable; depends more on protocol and indication than on device name alone.
- FDA 510(k) Summary K231790: Morpheus8 · accessdata.fda.gov
Session and recovery
| Attribute | Morpheus8 | Potenza |
|---|---|---|
| Downtime | Redness, swelling, crusting, pinpoint bleeding, tenderness, and temporary track marks can occur; deeper or higher-energy treatment can extend recovery. | Redness, swelling, tenderness, pinpoint bleeding, crusting, and temporary needle marks can occur. |
Downtime
- Morpheus8
- Redness, swelling, crusting, pinpoint bleeding, tenderness, and temporary track marks can occur; deeper or higher-energy treatment can extend recovery.
- Potenza
- Redness, swelling, tenderness, pinpoint bleeding, crusting, and temporary needle marks can occur.
Risks and limitations
| Attribute | Morpheus8 | Potenza |
|---|---|---|
| Documented risks | Pain, bleeding, infection, burns, pigment change, scarring, fat loss, contour change, nerve injury, and disfigurement. FDA issued a 2025 safety communication about serious complications reported with certain RF-microneedling uses. | Pain, bleeding, infection, burns, scarring, pigment change, fat loss, contour change, and nerve injury; the FDA's 2025 RF-microneedling safety communication applies to the procedure category. |
| Most likely disappointment | Device branding can obscure how strongly depth, energy, passes, tip, and provider judgment determine both result and risk.
| Many public claims describe cosmetic outcomes that are not the same as the device's narrow US cleared indication.
|
| When this treatment may not be appropriate | When the patient cannot accept thermal-injury risks, has active infection or impaired healing, or expects a result outside the supported device indication. | When active infection, impaired healing, implanted-device concerns, or unwillingness to accept thermal injury makes treatment unsuitable; exact IFU screening is required. |
| Provider-dependent variables | Needle depth, coated versus uncoated tip, energy per pin, pulse duration, passes, overlap, treatment endpoint, anatomy, anesthesia, and infection control. | Tip selection, insulated status, monopolar or bipolar mode, depth, energy, pulse duration, passes, overlap, anesthesia, and infection control.
|
| Skin-tone considerations | The K231790 clearance limits energy above 62 mJ per pin to Fitzpatrick skin types I–IV. Lower-energy treatment still requires individualized settings and pigment-risk counselling.
| RF is not melanin-targeted, but burns and post-inflammatory pigment change remain possible; no equivalence across all skin tones is inferred from clearance. |
Documented risks
- Morpheus8
- Pain, bleeding, infection, burns, pigment change, scarring, fat loss, contour change, nerve injury, and disfigurement. FDA issued a 2025 safety communication about serious complications reported with certain RF-microneedling uses.
- Potenza
- Pain, bleeding, infection, burns, scarring, pigment change, fat loss, contour change, and nerve injury; the FDA's 2025 RF-microneedling safety communication applies to the procedure category.
Most likely disappointment
- Morpheus8
- Device branding can obscure how strongly depth, energy, passes, tip, and provider judgment determine both result and risk.
- FDA 510(k) Summary K231790: Morpheus8 · accessdata.fda.gov
- Potenza
- Many public claims describe cosmetic outcomes that are not the same as the device's narrow US cleared indication.
- FDA 510(k) Summary K192545: Potenza · accessdata.fda.gov
When this treatment may not be appropriate
- Morpheus8
- When the patient cannot accept thermal-injury risks, has active infection or impaired healing, or expects a result outside the supported device indication.
- Potenza
- When active infection, impaired healing, implanted-device concerns, or unwillingness to accept thermal injury makes treatment unsuitable; exact IFU screening is required.
Provider-dependent variables
- Morpheus8
- Needle depth, coated versus uncoated tip, energy per pin, pulse duration, passes, overlap, treatment endpoint, anatomy, anesthesia, and infection control.
- Potenza
- Tip selection, insulated status, monopolar or bipolar mode, depth, energy, pulse duration, passes, overlap, anesthesia, and infection control.
- Potenza Physician Brochure · cynosure.com
Skin-tone considerations
- Morpheus8
- The K231790 clearance limits energy above 62 mJ per pin to Fitzpatrick skin types I–IV. Lower-energy treatment still requires individualized settings and pigment-risk counselling.
- FDA 510(k) Summary K231790: Morpheus8 · accessdata.fda.gov
- Potenza
- RF is not melanin-targeted, but burns and post-inflammatory pigment change remain possible; no equivalence across all skin tones is inferred from clearance.
Evidence and regulatory status
| Attribute | Morpheus8 | Potenza |
|---|---|---|
| United States regulatory status | FDA 510(k)-cleared, including K231790, for specified dermatologic and surgical electrocoagulation, hemostasis, and soft-tissue coagulation/contraction uses; high-energy use has a Fitzpatrick-type limitation.
| FDA 510(k)-cleared under K192545 for dermatologic and general surgical procedures for electrocoagulation and hemostasis. The clearance should not be rewritten as an FDA-cleared wrinkle or skin-tightening indication.
|
| Canadian regulatory status | Health Canada MDALL lists active Class III InMode fractional RF device licences that include Morpheus8 configurations; exact model and handpiece should be verified.
| Health Canada MDALL lists Potenza Fractional RF Microneedle Electrosurgical Unit under active Class III licence 106699.
|
| Evidence status | High for device mechanism, clearance boundaries, and current FDA safety warning; lower and heterogeneous for aesthetic protocol, session count, and durability.
| High for device identity, mechanism, and regulatory boundaries; limited for product-specific comparative efficacy, session count, and durability.
|
United States regulatory status
- Morpheus8
- FDA 510(k)-cleared, including K231790, for specified dermatologic and surgical electrocoagulation, hemostasis, and soft-tissue coagulation/contraction uses; high-energy use has a Fitzpatrick-type limitation.
- Morpheus8 510(k) clearance summary · accessdata.fda.gov
- FDA 510(k) database K231790 · accessdata.fda.gov
- Potenza
- FDA 510(k)-cleared under K192545 for dermatologic and general surgical procedures for electrocoagulation and hemostasis. The clearance should not be rewritten as an FDA-cleared wrinkle or skin-tightening indication.
- FDA 510(k) Summary K192545: Potenza · accessdata.fda.gov
Canadian regulatory status
- Morpheus8
- Health Canada MDALL lists active Class III InMode fractional RF device licences that include Morpheus8 configurations; exact model and handpiece should be verified.
- Health Canada MDALL: InMode licences · health-products.canada.ca
- Potenza
- Health Canada MDALL lists Potenza Fractional RF Microneedle Electrosurgical Unit under active Class III licence 106699.
- Health Canada MDALL: Jeisys Potenza licence · health-products.canada.ca
Evidence status
- Morpheus8
- High for device mechanism, clearance boundaries, and current FDA safety warning; lower and heterogeneous for aesthetic protocol, session count, and durability.
- FDA 510(k) database K231790 · accessdata.fda.gov
- Potenza
- High for device identity, mechanism, and regulatory boundaries; limited for product-specific comparative efficacy, session count, and durability.
- FDA 510(k) Summary K192545: Potenza · accessdata.fda.gov
SourcesShowHide
Sources are grouped by treatment so the support for each record stays visible.
Morpheus8
- FDA 510(k) database K231790 · accessdata.fda.gov, 2023-11-03 · supports 2 fields
- FDA 510(k) Summary K231790: Morpheus8 · accessdata.fda.gov, 2023-11-03 · supports 16 fields
- FDA Safety Communication: Potential Risks with Certain Uses of RF Microneedling · fda.gov, 2025-10-15 · supports 7 fields
- Health Canada MDALL: InMode licences · health-products.canada.ca
- Morpheus8 510(k) clearance summary · accessdata.fda.gov
Potenza
- FDA 510(k) Summary K192545: Potenza · accessdata.fda.gov, 2020-05-12 · supports 17 fields
- FDA Safety Communication: Potential Risks with Certain Uses of RF Microneedling · fda.gov, 2025-10-15 · supports 7 fields
- Health Canada MDALL: Jeisys Potenza licence · health-products.canada.ca
- Potenza Physician Brochure · cynosure.com, 2021-04-01
See average treatment prices near you
Enter a US ZIP code or Canadian postal code to check our stored estimate for the surrounding market.